Christensen E F, Dahl R
Department of Respiratory Diseases, University Hospital of Aarhus, Denmark.
Lung. 1991;169(6):325-33. doi: 10.1007/BF02714169.
Patients with chronic bronchitis were randomly allocated to 4 weeks treatment with terbutaline 0.5 mg inhaled through a cone spacer with an expiratory resistance creating a positive expiratory pressure (+PEP group) or without (-PEP group). The patients recorded their symptoms in a diary and peak expiratory flow (PEFR) was measured before and after each inhalation. PEFR increased significantly after inhaled terbutaline both with and without PEP. The mean increase in PEFR after terbutaline inhalations was significantly greater (p less than 0.0001) in the +PEP group (24 L/min) compared to the -PEP group (17 L/min). The +PEP group had less sputum and less difficulty with coughing up sputum compared to the -PEP group. This study showed a small but significant enhancement of the bronchodilation and a beneficial effect on symptoms when inhalation of beta-2-agonist was combined with PEP in patients with chronic bronchitis.
慢性支气管炎患者被随机分配，接受为期4周的治疗，一组通过带有呼气阻力以产生正呼气末压力的锥形间隔器吸入0.5毫克特布他林（+PEP组），另一组不使用呼气阻力（-PEP组）。患者在日记中记录症状，并在每次吸入前后测量呼气峰值流速（PEFR）。无论有无PEP，吸入特布他林后PEFR均显著增加。与-PEP组（17升/分钟）相比，+PEP组吸入特布他林后PEFR的平均增加幅度显著更大（p<0.0001）（24升/分钟）。与-PEP组相比，+PEP组痰液较少，咳痰困难也较少。这项研究表明，在慢性支气管炎患者中，吸入β-2激动剂与PEP联合使用时，支气管扩张作用虽小但显著增强，且对症状有有益影响。
